We see what others don't

About Mundipharma

Opens Page

Our medicines

Opens Page

Careers

Opens Page

Partnering

Opens Page

Latest News

Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Apr 16 2019

Opens Page

EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Mountain rescue study launches to investigate use of Penthrox® (methoxyflurane) for trauma-related pain in hostile environments

Mar 27 2019

Opens Page

FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY

Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

Mar 19 2019

Opens Page

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY


The Mundipharma global network of
independent associated companies:


.

Supporting patients and communities

As we live longer, providing good quality medical care becomes an increasingly challenging task for the healthcare sector.

Network capabilities

Since our founding by physician entrepreneurs in 1952, the Mundipharma network of independent associated pharmaceutical companies has served the needs of patients and healthcare providers around the globe by providing novel medicines that address unmet medical needs.

Sharing clinical trial information and results

Clinical trial results for studies managed by Mundipharma Research and more information on our disclosure policy are available here.